"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
| Descriptor ID |
D018501
|
| MeSH Number(s) |
D27.505.954.329
|
| Concept/Terms |
Antirheumatic Agents- Antirheumatic Agents
- Anti-Rheumatic Drugs
- Anti Rheumatic Drugs
- Antirheumatic Drugs
- Anti-Rheumatic Agents
- Anti Rheumatic Agents
Antirheumatic Drugs, Disease-Modifying- Antirheumatic Drugs, Disease-Modifying
- Antirheumatic Drugs, Disease Modifying
- DMARD
- Disease-Modifying, Antirheumatic Second-Line Drugs
- Disease Modifying, Antirheumatic Second Line Drugs
- Antirheumatic Disease-Modifying Second-Line Drugs
- Antirheumatic Disease Modifying Second Line Drugs
- Disease-Modifying Antirheumatic Drugs
- Disease Modifying Antirheumatic Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".
This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 4 | 1 | 5 |
| 2010 | 3 | 2 | 5 |
| 2011 | 4 | 1 | 5 |
| 2012 | 3 | 0 | 3 |
| 2013 | 5 | 0 | 5 |
| 2014 | 1 | 0 | 1 |
| 2015 | 5 | 1 | 6 |
| 2016 | 5 | 3 | 8 |
| 2017 | 8 | 2 | 10 |
| 2018 | 7 | 3 | 10 |
| 2019 | 10 | 2 | 12 |
| 2020 | 3 | 0 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 10 | 0 | 10 |
| 2023 | 9 | 0 | 9 |
| 2024 | 2 | 3 | 5 |
| 2025 | 0 | 1 | 1 |
| 2026 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.
-
Predicting the risk of venous thromboembolism events in older adults with rheumatoid arthritis after initiating targeted disease-modifying antirheumatic drugs: a comparison of the random survival forest and regularized cox regression models. Curr Med Res Opin. 2026 Mar; 42(3):615-630.
-
Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study. Lancet Rheumatol. 2026 Jul; 8(7):e550-e562.
-
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study. Semin Arthritis Rheum. 2026 Jun; 78:152983.
-
Long-Term Outcomes in Seronegative Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2026 Aug; 78(8):998-1005.
-
Interpretable Ensemble Machine Learning Prediction of Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults With Rheumatoid Arthritis. Clin Ther. 2026 Mar; 48(3):214-225.
-
Phytoconstituents as therapeutic agents in combating methotrexate-induced hepatotoxicity and nephrotoxicity. Expert Opin Drug Metab Toxicol. 2025 Nov-Dec; 21(11-12):1287-1305.
-
Rituximab Treatment in Adult Patients With Idiopathic Inflammatory Myositis: A Systematic Review and Meta-analysis. J Clin Rheumatol. 2025 Jan 01; 31(1):33-39.
-
Interleukin-6 receptor antagonists in pregnancy: a reason for cautious optimism. Lancet Rheumatol. 2024 09; 6(9):e592-e593.
-
Methotrexate: Borrowed Hope for Persons With Knee Osteoarthritis? Ann Intern Med. 2024 09; 177(9):1271-1272.
-
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2024 Jun; 23(6):687-714.